Tilray Brands, Inc.
TLRYHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Tilray Brands, Inc. (TLRY) is listed under Drug Manufacturers - Specialty & Generic. The $540.7M market capitalization puts TLRY squarely in small-cap range for its industry. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness.
Market Cap
$540.7M
Beta
1.90
P/E (TTM)
—
P/E (Fwd)
17.10
EPS (TTM)
$-14.65
EPS (Fwd)
$0.26
ROE
-63.2%
ROA
-1.5%
Cash
$425.7M
Total Debt
$343.9M
Free CF
-$31.1M
52W Change
-27.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $425.7M in cash comfortably exceeding the $343.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$31.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -63.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $628.4M (2022) to $821.3M (2025), reflecting a 31% increase over the period.
A beta of 1.90 means TLRY is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TLRY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.